Davis Polk advised Goldman, Sachs & Co. and J.P. Morgan Securities LLC as representatives of the several underwriters in connection with an SEC-registered  secondary offering of 5,175,000 shares of common stock of Zeltiq Aesthetics, Inc. by entities affiliated with Advanced Technology Ventures, Aisling Capital III, LP and Venrock Associates V, L.P. The shares of common stock sold included 675,000 shares sold pursuant to the underwriters’ fully exercised option to purchase additional shares. The offering resulted in gross proceeds of approximately $67 million. Zeltiq’s common stock is listed on the NASDAQ Global Select Market under the symbol “ZLTQ.” 

Zeltiq is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. Zeltiq’s first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth Hooton Ruiz and Jeffrey Hedrick. Partner Rachel D. Kleinberg and associate Catherine Paskoff Chang provided tax advice. Associate Dan Karmel provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Katie Young, Cassandra Aguirre, and Sorina Delia Lazar were the legal assistants on the transaction. Members of the Davis Polk team are based in the Menlo Park and New York offices.